“showed a trend”

Microglial depletion caused a slight, but not significant, decrease in GFAP intensity in wild-type mice, and PLX-treated ATXN1[82Q] mice showed a trend toward a decrease in GFAP expression (Fig. 4b , one-way ANOVA, p > 0.05).

Effect of Niacin on Alpha Diversity Analysis Relative to the CTX group, the HNA group showed a trend toward higher alpha diversity, as measured by the Chao1, Ace, Shannon, and Simpson indices ( Figure 9 A–D; p < 0.05).

The odds of death in those with retinopathy showed an increase, although this only showed a trend (OR 1.13 95%CI 1.0–1.28 p = 0.05) while neuropathy failed to show an association [OR 1.19 (95%CI 0.95–1.50); p = 0.13].

Subgroup analysis for patients with adhesion showed a trend towards an increase in clinical pregnancy rate in the ≤ 120 days group compared to > 120 days group (RR = 0.79, 95% CI 0.62-1.00, P = 0.05; heterogeneity: not applicable, Fig. 6 B), however, statistical significance was not reached.

Almost reaching significance was the presence of PETs other than gastrinomas in patients with an MEN1-related death (47% vs 33%, p = 0.058), whereas thyroid disease showed a trend toward higher occurrence in patients with a non-MEN1-related death (0 vs 2.95%, p = 0.050).

A2 deletion showed a trend toward decreasing Drp1 levels after I/R. ∗P < 0.05 vs.

No significant differences were noted in the UPDRS III motor scores, even though women showed a trend towards having worse bradykinesia ( P = 0.05) and axial motor ( P = 0.07) scores compared to men during ON.

To explore which patients could have potential DFS benefit from RT, we also performed subgroup analyses and observed that patients with PI as well as those without resection for primary tumor showed a trend to benefit from RT, but with a P value > 0.05.

2.6 ± 0.2 g on HFD; main effect p < 0.05), while adipose tissue showed a trend for lower values (1.0 ± 0.2 vs. 1.3 ± 0.1 g on STD; 2.5 ± 0.2 vs. 2.7 ± 0.2 g on HFD; p > 0.05) (Fig. 1E, F ).

Overall, FmRP and FmSY showed a trend of no significant differences ( p > 0.05) in most amino acid types, while FmSZ exhibited significant differences ( p < 0.05) compared to the other two populations.

At the beginning of the trial, males showed a trend toward choosing the EO-treated arm, although no statistical differences were found (χ 2 = 2.46; p > 0.05), whereas females showed a preference for the EO-treated arm (χ 2 = 4.17; p = 0.04) ( Table 2 ), but no significant differences were observed at the end of the trial (χ 2 =3.11; p > 0.05).

Texture and aftertaste acceptance showed a trend similar to that of sweetness intensity ( p < 0.05).

Multiple comparison results indicated that MCE supplementation significantly increased HDL-C concentration ( p < 0.01) and showed a trend toward lower LDL-C in the S1 group ( p < 0.05).

Metformin-treated mice showed a trend to spend less time in annulus 40 area as compared to the controls, which reached significance for session 5 ( Figure 4A , p <0.05).

Patients undergoing PT showed a trend toward a more favorable outcome compared to those not receiving treatment, although this difference did not reach statistical significance (CGI-C 2 vs. 3, p = 0.050) ( Figure 3 ).

Notably, although the mean of SubA showed a trend towards difference among the benign group, malignant group, and inflammatory group (21.2±11.1 vs. 34.5±16.6 vs. 43.9±10.7 HU, respectively; all P<0.05).

Overall, GI-MEN clones showed a trend towards higher chromosome copy number diversity than SK-N-AS clones (mean 14% compared to 8% of cells with copy number outside the modal value; p = 0.05), consistent with the higher rate of mitotic segregation errors in the former cell line.

In addition, we evaluated changes for genes NefH and Ngf, also involved in axonal function, growth, maintenance and neuron survival ( Ryden et al., 1997 ; Hayakawa et al., 2012 ; Turney et al., 2016 ; Fornaro et al., 2020 ) although changes between vehicle and boldine SCI samples were not significant and only showed a trend ( Supplementary Figures 9G, H ; p > 0.05).

Later age of symptom onset (70+ years) was associated with lower odds of genetic testing completion (OR 0.23; 95% CI 0.12–0.43; P < 0.001) compared to the reference group (10–19 years), while early symptom onset (0–9 years) showed a trend toward higher odds of genetic testing completion that approached but did not reach statistical significance (OR 1.53; 95% CI 1–2.37; P = 0.05).

The sibutramine group showed a trend toward a greater reduction in body fat percentage than the placebo group (p = 0.05).

High TPR expression was significantly associated with improved 28-day survival (log-rank P = 0.0048), whereas high ERN1 expression showed a trend toward poorer survival (log-rank P = 0.05) (Fig. 5 G–H).

Age had a significant level of correlation with walking program adherence ( n = 8, r = 0.72, p = 0.019), and it showed a trend with exercise program adherence ( n = 7, r = 0.60, p = 0.05).

Although the mice treated with VV-α-TIGIT only showed a trend of lower tumor volume compare to mice treated with VV-Control ( P > 0.05) ( Fig. 5 F ), these mice demonstrated a significantly longer survival time than mice treated with VV-Control ( P <0.01) ( Fig. 5 G ).

However, coadministration of SV and GJ (HSG1) up-regulated the mRNA expressions of iNOS and COX-1 ( p < 0.05) and showed a trend of elevating the mRNA level of COX-2 ( p > 0.05).

Compared with the FMT‐spost group, transplanting feces from pre‐inoculation group also showed a trend of shrinking tumor volume, though not reaching the statistic threshold ( P > 0.05).